EFFECTIVE TREATMENT has altered the natural history of many malignancies. This is well illustrated by the emergence of central nervous system (CNS) disease during prolonged remission of children with acute lymphoblastic leukaemia (ALL). Children developing leukaemic infiltration of the CNS relapse systemically earlier than those who do not. Prophylactic therapy designed to prevent such CNS relapse has led to a significant improvement in survival and to possible cures (Aur et al., 1972) .
The results of treatment of adult ALL are less satisfactory than those achieved for childhood acute leukaemia, but nonetheless improvements in survival have also been achieved (Clarkson et al., 1975) . On the basis of childhood studies, it seems likely that prophylactic CNS treatment will contribute to improved survival in adult patients achieving complete remission. The incidence of CNS involvement in adult ALL has received less attention than that in childhood. Analysis is complicated by the fact that some studies include both children and adults.
Nies, Thomas and Freireich (1965) compared the incidence of meningeal leukaemia in two series of patients with ALL, the first diagnosed between 1953 and 1958 and the second between 1961 and 1963. The incidence of symptomatic CNS disease was the same in both groups, despite improved survivals in the latter study. However, the overall incidence of CNS involvement was 25% in the first group and 42% in the second. The difference was accounted for by the detection of asymptomatic disease by cerebro-spinal fluid (CSF) examination in the second study. A real increase in the incidence of CNS involvement in association with prolonged survival is suggested by Pavlovsky, Eppinger-Helft and Muriel (1973) and Wolk et al. (1974 November 1972 and June 1976 were treated with a standard protocol (OPAL). The diagnosis was established by examination of peripheral blood and bone marrow aspirate smears. Acute non-myelogenous leukaemia was diagnosed when the frequency of blasts in the bone marrow exceeded 3000 and when these showed no evidence of myeloid differentiation. Three categories of acute non-myelogenous leukaemia were recognized; ALL was identified on the basis of infiltration with blast cells of lymphoid appearance on Romanowsky staining, which were Sudan Black negative and some of which showed " block positive " staining with the Periodic Acid-Schiff (PAS) reaction. ABLL was recognized when the infiltrating blastic cells had deeply basophilic vacuolated cytoplasm on the Romanowsky stain (Berard et al., 1969) . These were all negative with the PAS reaction. A final category included those cases in which the infiltrating cells were not morphologically lymphoid or myeloid, and negative with both Sudan Black and PAS (AUL).
OPAL protocol.-The combination of vincristine and prednisolone, although highly effective in childhood ALL, is less effective in the adult variants. In consequence, Erwinia asparaginase (Porton) (10,000 u/M2) and prednisolone (40 mg CSF examination was carried out within 1 h of lumbar puncture; the smears were made using the cytocentrifuge (Shandon). Aliquots (0.5 ml) of CSF were centrifuged in duplicate at 1000 rev/min for 5 min. The smears were dried and then stained by MayGrunwald-Giemsa. Cytochemical stains were also employed if appropriate, but in practice these were not usually helpful in deciding whether there was leukaemic infiltration. Following examination of the stained preparations, samples were categorized into " negative ", " infiltrated " or " infiltration suspected ". Infiltration was diagnosed when there were at least 5 leukaemic blast cells present in the cytocentrifuged deposit. The number 5 w%Aas chosen on an empirical basis. Samples were classified as negative when no leukaemic blast cells could be identified, even when the total white count was otherwise raised. Infiltration was suspected when an occasional blast cell could be identified, but the total of blast cells seen in the deposit was <5. The appearance of cells in the deposit with a high nuclear/cytoplasmic ratio and slightly immature chromatin, frequently with irregular and scanty cytoplasm, was also regarded as suspicious of infiltration. Following treatment, CNS remission was accepted when 2 consecutive CSF deposits were free from blast cells.
RESULTS
Forty-seven cases were treated using the OPAL protocol and there were 31 complete remissions (details in Table I ). (Tables III  and IV) There were 31 patients in this group. Four out of 28 patients with ALL were found to have definite blast cells in the CSF, either on the first or on subsequent CSF examinations during early CNS therapy (Table III) . A further 6 patients with ALL had suspicious cells in the CSF during the same period (Table IV) . Since the significance of the suspicious cells was uncertain, and might have been related to intrathecal methotrexate, no further specific therapy was given. CSF examination was repeated in 5 of the patients with a suspicious CSF 1 month after therapy was completed. In 4 of these cases, the CSF was clear, but in the fifth there was infiltration which persisted to the time of death. One of the 4 remaining patients has since relapsed, and examination of the CSF at the time of his second clinical remission revealed infiltration from which he subsequently died. The 2 cases ABLL had definite infiltration of the CSF at the time of clinical and haematological remission (Table III) and the 1 case of acute undifferentiated leukaemia had suspicious cells in the CSF throughout the period of CNS therapy, but none at the time of CSF examination 1 month following completion of therapy (Table  IV) .
DISCUSSION
This study reveals a high incidence of early CNS leukaemia in adults with ALL and ABLL ( Table V) . The appa- (Aur et al., 1972 (Aur et al., , 1973 M. R. C., 1973; Muriel et al., 1974) provided therapy is given before the advent of symptomatic CNS involvement. Cranio-spinal irradiation at the time of complete remission has been compared with a group of patients who received no such therapy, by Aur et al. (1972) . Only 2/45 of his patients who received cranio-spinal irradiation relapsed, compared with 27/49 patients not receiving cranio-spinal therapy. An important observation in this study was that therapy designed to eradicate the disease in the 27 patients who relapsed in the CNS was unsatisfactory.
Evidence is accumulating that there is a strong case for starting CNS therapy during remission induction in adults with acute non-myelogenous leukaemia. This is based on our finding of CNS disease at the time of definitive clinical and haematological remission, and the results of studies in childhood acute leukaemia which suggest that prophylactic therapy against CNS disease may contribute towards prolonging disease-free survival to the point of cure. Since the risks of early involvement of the CNS in ABLL appear to be very high indeed, remission induction therapy should be planned to allow CNS treatment from the outset. This study has also indicated a significant risk of CNS involvement early in the management of ALL. Since intrathecal therapy during remission induction may prevent the emergence of clinically evident CNS involvement, we also advocate this approach to the management of adult ALL. The value of CNS therapy in the management of patients with consistently negative CSF examination should become apparent from follow-up studies.
It is clear from this study that regular cytological examination of the CSF plays an important part in the management of patients with adult acute non-myelogenous leukaemia. Until effective therapy can be determined for CNS leukaemia, the proven advantage of prophylactic therapy must be exploited to the full, and in view of the apparent risk of the early development of CNS disease it is clear that this treatment should start as early as possible during remission induction in adult patients with acute non-myelogenous leukaemia.
